1. Scrip

Coronavirus Update: Moderna Snags Vaccine EUA

Plus: NIAID Test Antibodies In Hospitalized Patients, Asia Developments

 
• By Scrip Team

The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.

Doctor, nurse, scientist hand in blue gloves holding flu, measles, coronavirus, covid-19 vaccine disease preparing for child, baby, adult, man and woman vaccination shot, medicine and drug concept.
Moderna is second to win emergency authorization for a vaccine against SARS-CoV-2 • Source: Shutterstock

The US Food and Drug Administration (FDA) has given an emergency use authorization (EUA) to Moderna, Inc.’s vaccine against the SARS-CoV-2 virus, mRNA-1273, just a week after granting one to Pfizer Inc. and BioNTech SE’s BNT162b2. Yet, despite the two products’ similarity, Moderna’s has not yet shown cases suggesting anaphylaxis in people receiving it.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.